Radiant Innovation Asset Resilience Ratio
Radiant Innovation asset resilience ratio. Radiant Innovation (3373) has an Asset Resilience Ratio of 0.82% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 3373 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Radiant Innovation (2017–2025)
Asset resilience ratio of Radiant Innovation from 2017 to 2025. This chart shows how Radiant Innovation's Asset Resilience Ratio has changed over time. Read 3373 liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Radiant Innovation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Radiant Innovation total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$7.01 Million | 0.82% |
| Total Liquid Assets | NT$7.01 Million | 0.82% |
Asset Resilience Insights
- Limited Liquidity: Radiant Innovation maintains only 0.82% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Radiant Innovation Industry Peers by Asset Resilience Ratio
Compare Radiant Innovation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Applied BioCode
TW:6598 |
Medical Devices | 9.75% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Cleo Diagnostics Ltd
AU:COV |
Medical Devices | 94.64% |
|
Impedimed Ltd
AU:IPD |
Medical Devices | 46.15% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
Radiant Innovation Asset Resilience Ratio by Year (2017–2025)
Radiant Innovation asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Radiant Innovation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.04% | NT$8.94 Million ≈ $281.75K |
NT$861.31 Million ≈ $27.14 Million |
-0.13pp |
| 2024-12-31 | 1.17% | NT$10.95 Million ≈ $344.86K |
NT$935.42 Million ≈ $29.47 Million |
-0.16pp |
| 2023-12-31 | 1.33% | NT$13.01 Million ≈ $409.76K |
NT$979.30 Million ≈ $30.85 Million |
+0.14pp |
| 2022-12-31 | 1.18% | NT$13.23 Million ≈ $416.75K |
NT$1.12 Billion ≈ $35.18 Million |
+0.13pp |
| 2021-12-31 | 1.05% | NT$13.03 Million ≈ $410.36K |
NT$1.24 Billion ≈ $39.07 Million |
+0.14pp |
| 2020-12-31 | 0.91% | NT$17.46 Million ≈ $550.05K |
NT$1.92 Billion ≈ $60.64 Million |
-3.15pp |
| 2017-12-31 | 4.06% | NT$32.66 Million ≈ $1.03 Million |
NT$804.84 Million ≈ $25.36 Million |
-- |
About Radiant Innovation
Radiant Innovation Inc. engages in the design and development of infrared technology products. It offers medical infrared thermometers, including infrared ear, non-contact forehead, and multi-function thermometers, as well as probe cover; industrial infrared thermometers; and CO2 monitors. Radiant Innovation Inc. was founded in 1989 and is headquartered in Hsinchu City, Taiwan.